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Abstract
Background: The risks of long term sequelae from childhood pneumonia have not been systematically assessed. The aims
of this study were to: (i) estimate the risks of respiratory sequelae after pneumonia in children under five years; (ii) estimate
the distribution of the different types of respiratory sequelae; and (iii) compare sequelae risk by hospitalisation status and
pathogen.
Methods: We systematically reviewed published papers from 1970 to 2011. Standard global burden of disease categories
(restrictive lung disease, obstructive lung disease, bronchiectasis) were labelled as major sequelae. ‘Minor’ sequelae (chronic
bronchitis, asthma, other abnormal pulmonary function, other respiratory disease), and multiple impairments were also
included. Thirteen papers were selected for inclusion. Synthesis was by random effects meta-analysis and meta-regression.
Results: Risk of at least one major sequelae was 5.5% (95% confidence interval [95% CI] 2.8–8.3%) in non hospitalised
children and 13.6% [6.2–21.1%]) in hospitalised children. Adenovirus pneumonia was associated with the highest sequelae
risk (54.8% [39.2–70.5%]) but children hospitalised with no pathogen isolated also had high risk (17.6% [10.9–24.3%]). The
most common type of major sequela was restrictive lung disease (5.4% [2.5–10.2%]) . Potential confounders such as loss to
follow up and median age at infection were not associated with sequelae risk in the final models.
Conclusions: All children with pneumonia diagnosed by a health professional should be considered at risk of long term
sequelae. Evaluation of childhood pneumonia interventions should include potential impact on long term respiratory
sequelae.
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Introduction
Pneumonia is the most common cause of mortality in children
under five years of age. Almost 200 million new episodes of
pneumonia occur each year in children under five years, 95% of
them in developing countries. 10% are severe enough to be life-
threatening and require hospital admission [1,2].
It is well known that children with immunodeficiency and cystic
fibrosis have long term respiratory problems such as recurrent
pneumonia, bronchiectasis and restrictive lung disease [3]. Children
and adults from marginalised and Indigenous populations also have
recurrent pneumonia and frequent hospital admissions [4,5]. Long
term respiratory sequelae from pathogens such as Adenovirus and
Mycoplasma pneumoniae have also been well documented including
severe problems such as bronchiectasis and bronchiolitis obliterans,
a respiratory disease in which the bronchioles are compressed and
narrowed by inflammatory products and fibrosis [3,6].
However, there is poor understanding of long term respiratory
outcomes from pneumonia in children without risk factors or highly
virulent pathogens; especially outcomes for children who have not
been hospitalised. This information is needed to ensure that children
with pneumonia are correctly managed by health professionals after
they have recovered from their acute illness. These data are also
needed to accurately assess the total long term burden of disease
from childhood pneumonia and to understand the full impact of
interventions against childhood pneumonia (e.g. vaccines against
Streptococcus pneumoniae and reduction of indoor air pollution).
The aims of this study were to: (i) estimate the risks of
respiratory sequelae after pneumonia in children under five years;
(ii) estimate the distribution of the different types of respiratory
sequelae; and (iii) compare sequelae risk by hospitalisation status
and pathogen.
Methods
This study was conducted using the PRISMA (Preferred
reporting items for systematic reviews and meta-analyses)
guidelines [7].
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31239
Definitions
A case of ‘pneumonia’ was defined as any child under five years
with clinical signs of pneumonia as diagnosed by a health
professional (Table 1). Hospital pneumonia was defined as a child
requiring hospitalisation for pneumonia. Non hospital pneumonia
was defined as a child with no hospitalisation or whose hos-
pitalisation status was unknown. Pathogen specific pneumonia was
defined as any child under 5 years with clinical signs of pneumonia
plus laboratory evidence (in blood or lung aspirate) of a recognised
pneumonia pathogen e.g. Streptococcus pneumoniae, Haemophilus
influenzae type b, Staphlococcus aureus, Adenovirus Mycoplasma
pneumoniae, Chlamydia pneumoniae, or Respiratory syncitial virus.
Non pathogen specific pneumonia was defined when laboratory
tests were not performed or were inconclusive. Radiologically
confirmed pneumonia was defined as radiological areas of opacity
representing consolidation according to WHO criteria [8,9].
A ‘sequela’ was defined according to the 2001 global burden of
disease (GBD) priorities project as a health state resulting from
pneumonia for which epidemiological estimates (incidence,
prevalence, average duration) and a single average disability
weight could be calculated [10,11]. It included all current and
future functional health states (until remission to full health or
death) in the natural history of the disease that impaired quality of
life or activities of daily living. The 2001 GBD project defined a
group of specific sequelae domains (Table 2) which we retained for
use in this study (restrictive lung disease, obstructive lung disease,
bronchiectasis) and labelled as ‘major’ sequelae [10]. We also
collected data on other respiratory sequelae diagnosed by medical
professionals but labelled these as ‘non GBD’ ‘minor’ sequelae
(chronic bronchitis, asthma, other abnormal pulmonary function,
other respiratory disease). A separate category was also created to
identify individuals with more than one sequela (multiple
Table 1. Pneumonia case definitions.
Hospital pneumonia Any child under 5 years with clinical signs of pneumonia as diagnosed by a health professional that required
hospitalisation
Non hospital pneumonia Any child under 5 years with clinical signs of pneumonia as diagnosed by a health professional that did not require
hospitalisation or hospitalisation status was unknown
Pathogen specific pneumonia Any child under 5 years with clinical signs of pneumonia as diagnosed by a health professional with laboratory
evidence (in blood or lung aspirate) of recognised pneumonia pathogen eg Streptococcus pneumoniae, Haemophilus
influenzae type b, Staphlococcus aureus, Mycoplasma pneumoniae, Chlamydia pneumonia, Adenovirus, Respiratory
syncitial virus
Non pathogen specific pneumonia Any child under 5 years with clinical signs of pneumonia as diagnosed by a health professional where laboratory
tests were not performed or were inconclusive
doi:10.1371/journal.pone.0031239.t001
Table 2. Sequelae domains and case definitions.
‘GBD’ ‘Major’ case definitions (ICD10 codes)
Restrictive lung disease (J43) Impaired lung function as measured by a reduced forced vital capacity (FVC) and a normal forced expiratory
volume in 1 second (FEV1) to FVC ratio. Person has mild, moderate or severe breathing difficulties with or
without wheeze
Obstructive lung disease (J44) Impaired lung function as measured by a reduced FEV1 and a low FEV1 to FVC ratio. The impaired lung
function does not improve significantly with bronchodilator therapy. Person has mild, moderate or severe
breathing difficulties with wheeze which does not improve significantly with bronchodilator therapy
Bronchiectasis (J47) Respiratory disease with localised, irreversible dilatation of part of the bronchial tree. Involved bronchi are
dilated, inflamed, and easily collapsible, resulting in airflow obstruction and impaired clearance of secretions.
Person has production of excessive amounts of sputum and frequent respiratory tract infections with or
without wheeze
Multiple impairments At least two of the above major domains
‘NonGBD’ ‘Minor’ case definitions (ICD10 codes)
Chronic bronchitis (J41, J42, J44) Chronic suppurative respiratory disease without bronchial dilatation or signs of bronchiectasis. Person has
production of excessive amounts of sputum and frequent respiratory tract infections with or without wheeze.
Asthma (J45) Impaired lung function as measured by a reduced FEV1 and a low FEV1 to FVC ratio. The impaired lung
function does improve significantly with bronchodilator therapy. Person has mild, moderate or severe
breathing difficulties with wheeze which does improve significantly with bronchodilator therapy.
Other abnormal pulmonary function (R94.2) Impaired lung function as measured by FEV1 or FVC which does not satisfy criteria above.
Other chronic respiratory disease. (J98.9) Other defined respiratory disease not classified above as diagnosed by a health professional using standard
tools (eg questionnaires)
Multiple impairments At least two of the above minor domains
GBD=Global Burden of Disease Project.
ICD10 = International Classification of Diseases, 10th edition.
FVC = Forced vital capacity (FVC).
FEV1 = Forced expiratory volume in 1 second.
doi:10.1371/journal.pone.0031239.t002
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impairments), as pneumonia can result in damage to a number of
different loci within the respiratory system (eg bronchi and lung
parenchyma) and deficits in many different domains. All sequelae
were allocated an International Classification of Diseases Version
10 (ICD10) code [12].
Search strategy and selection criteria
The initial search aimed to be as inclusive as possible using search
terms ‘‘Pneumonia’’ AND ‘‘complications’’ [Subheading] Limits:
Human, 1970/01/01-2011/11/01 (Figure 1). We searched Med-
line, WHOLIS, EMBASE, CINAHL Plus, and Web of Science
databases. We also reviewed reference lists of articles to identify
additional papers and reports and contacted experts in the field to
seek unpublished data and data that may have been missed by our
search. There were no language restrictions.
Papers were excluded if they did not report on: a defined
denominator of pneumonia patients (e.g. case series were
excluded); sequelae of pneumonia (e.g. studies that only reported
associated conditions such as septicaemia or arthritis were
excluded); health/functional states; original data (e.g. reviews,
repeated datasets were excluded); if they did not describe data
representative of the whole population of children (e.g. studies
containing only information on very high risk groups [e.g. cystic
fibrosis, immunodeficiency] were excluded); and if the papers did
not include any children who were under five years at the time of
the pneumonia episode. Papers were also excluded if they did not
examine for sequelae using standard tools (e.g. self reported
conditions were excluded).
We also assessed the quality of the included studies with the
Newcastle-Ottawa scales for assessing the quality of observational
studies in meta-analyses [13]. We assigned risk of bias (low,
moderate, and high risk of bias) as described by the Cochrane
Handbook [14].
Data extraction
Two reviewers examined titles, abstracts, and papers indepen-
dently using identical case definitions, data abstraction forms and
selection criteria. Disagreements were resolved by consensus
between the two reviewers and the lead authors.
We collected basic data on author, study date, the number of
children with pneumonia, the number of children who were
followed up, duration of follow up, the final number who were
examined for sequelae and classified the type of sequelae as major
and minor according to the case definitions in Table 2. We also
collected data on potential explanatory variables i.e. variables that
may explain variance in risk of sequelae. For each study, categories
for explanatory variables were created after an initial review of the
data as follows: cause of pneumonia (pathogen specific vs non
pathogen specific), hospitalisation status (hospitalised vs not
hospitalised), study design (prospective vs retrospective), median
Figure 1. Search strategy.
doi:10.1371/journal.pone.0031239.g001
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age at infection (,2 years vs $2 years), gender (proportion male
,50% vs $50%), duration of follow up (,2 years vs $2 years),
proportion of individuals with pneumonia who were lost to follow
up (,25% vs $25%). We also used data obtained from 2009
World Bank, World Health Organisation (WHO) and Child
Health Epidemiology Reference Group (CHERG) data sets
[15,16,17] to categorise countries into WHO region (African,
South East Asian, Western Pacific, Eastern Mediterranean,
European, and American regions), and GNI band in $US per
capita from the year 2009 (low income, low middle income, high
middle income, high income).
We also looked for data on other variables that are known to
increase risk of respiratory sequelae such as birthweight,
prematurity, pre-existing respiratory function (eg need for
ventilatory support at birth), indoor air pollution, cigarette
smoking, atopy and previous episodes of pneumonia but the
classifications used were disparate and the data could not be
synthesised. Where data were reported for multiple time periods,
the most recent data were used.
Analysis
Our initial review indicated that sequelae risk was heteroge-
neous and influenced by hospitalisation status and pathogenic
cause. Thus we decided to present risks stratified into four groups
(hospital pathogen specific, hospital nonpathogen specific, non-
hospital pathogen specific, nonhospital nonpathogen specific) and
to use random effects meta-analytic techniques to estimate the
pooled risk of developing at least one major and minor sequela
within these strata. We also used random effects meta analysis to
calculate risks in each sequelae domain (restrictive lung disease,
obstructive lung disease, bronchiectasis, chronic bronchitis,
asthma, other disease and multiple disease).
Multi-level mixed-effects logistic regression was used to
investigate the effect of hospitalisation status, pathogenic cause
and other explanatory variables on pneumonia sequelae estimates.
Pathogenic cause and hospitalisation status were included apriori in
all models. Crude and adjusted odds ratios and their 95% CI were
calculated. Statistical analyses were performed using STATA
Release 12 statistical software (Stata, College Station, TX, USA).
Results
Search results
2984 papers published between 1st January 1970 to 1st
November 2011 were identified from the Medline search and 67
titles were retained (Figure 1). No additional articles were obtained
from the WHOLIS, EMBASE, CINAHL Plus and Web of
Science searches, experts in the field and reference lists. No
unpublished data that met our inclusion criteria were identified.
13 papers were retained after the abstracts were reviewed and
our inclusion criteria were applied (Table 3). Three papers
investigated sequelae risk in children who were not hospitalised
[18,19,20], and none of these papers included pathogenic causes.
Ten papers investigated sequelae risk in hospitalised children (3
nonpathogenic cause [21,22,23], 7 pathogenic cause [2 Adenovi-
rus [24,25], 3 Mycoplasma pneumoniae [26,27,28], 1 Staphlococcus
aureus [29], 1 Chlamydia pneumoniae [30]) Radiological confirmation
was available for all hospital studies but no non hospital studies.
Overall, 722 children with pneumonia were examined for
sequelae (median number of children per study 38, interquartile
range [IQR] 22–62) (Table 1) and 77 had major sequela. 439
(60.8%) children were under 2 years at the time of the pneumonia
episode and none had risk factors. Characteristics of the 13
included studies are presented in Table 3 and full details can be
found in Appendix S1.
Only one study had a duration of follow up of less than 2 years
and the median duration of follow up was 10.8 years (IQR 2.1–
17.0]. Five (38%) studies reported loss to followup rates under 25%
and the median loss to follow up in all the studies was 34% (IQR
12–45%]). Six (46%) studies were prospective. 46% papers were
from Europe, 23% from the Western Pacific region, and 15%
were from the Americas and Africa. There were no papers from
the Eastern Mediterranean or South East Asian regions. Ten
(77%) papers were from high income countries and only one
(5.9%) paper was from a low income country.
To assess whether any publication bias was likely in our paper
we performed scatter plots of sequela risk against sample size and
standard error but no correlation was found (p value = 0.305).
Sequelae estimates
Risk of at least one major sequela was 5.5% (95% confidence
interval [95% CI] 2.8–8.3%) in non hospitalised children (Table 4)
and 13.6% [6.2–21.1%]) in hospitalised children. Figure 2 displays
the risk of at least one major pneumonia sequela by hospital site and
pathogenic cause. Risk appeared homogeneous within all strata; the
I2 (the percentage of variation attributable to heterogeneity) was
below 15% for all analyses. Adenovirus pneumonia was associated
with the highest sequelae risk (54.8% [39.2–70.5%]) but children
hospitalised with no pathogen isolated also had high risk (17.6%
[10.9–24.3%]). Risk of developing at least one minor sequela was
1.6% (1.0–8.5%) in non hospitalised children and 7.1% (1.0–13.4%)
in hospitalised children (Table 4) .
Domains
All participants were examined for all major (restrictive lung
disease, obstructive lung disease, bronchiectasis) and minor
(chronic bronchitis, asthma, other abnormal pulmonary function,
other respiratory disease) domains (Table 4). The most common
type of major sequela was restrictive lung disease (5.5 [2.5–
10.2%]). Bronchiectasis was only reported after hospitalised
pneumonia (0.9% (0.7–8.7%) and obstructive lung disease was
only reported after adenovirus pneumonia 2.8% (0.8–6.4%). The
most common type of minor sequela was chronic bronchitis 2.8%
(1.8–8.1%) followed by asthma 0.7% (0.2–4.2%). The only
multiple sequelae syndromes reported were bronchiectasis com-
bined with restrictive lung disease (1.2% [0.05–7.7%]) and chronic
bronchitis combined with asthma (3.2% [0.1–5.1%]) (Table 4). All
risks were higher in hospitalised than non hospitalised children.
Explanatory factors
Table 2 shows the results from the crude and adjusted random
effects logistic regression analysis of the effect of important factors
(pathogenic cause, site, age at infection, duration of follow up, loss
to follow up, gender, study design, WHO region, GNI band) on
pneumonia sequelae risk in children under five years.
The only factor that appeared predictive of pneumonia risk in
the univariable analysis was the proportion of children lost to
follow up (,25% vs $25%) (Table 5). However, this did not
remain significant in the multivariable analysis and there was no
evidence of a trend in risk of sequelae when loss to follow up was
examined as a continuous variable (odds ratio [OR] 0.036
[0.0005–2.45] p value = 0.123). Young children under two years
of age had a higher risk of sequelae (13.4% (4.5–22.3%)) compared
to older children 8.7% (3.1–14.3%) but this difference was not
statistically significant (OR 0.82 [0.14–4.67]).
The final multivariable model adjusted for the effects of
pathogenic cause, hospitalisation status and loss to follow up. In
Pneumonia and Sequelae
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this model only hospitalisation status remained strongly associated
with major pneumonia sequelae risk; there was a 3 fold greater risk
of sequelae in children hospitalised with pneumonia than non
hospitalised children (adjusted OR 3.65 [1.96–6.80]).
Discussion
We reported an overall risk of long term major respiratory
sequelae from childhood pneumonia in non hospitalised children
of 5.5% . Risk was three times higher in hospitalised children.
Children hospitalised with no pathogen isolated had a 20%
increase in risk. More than half of the children hospitalised
with adenovirus pneumonia were reported to have respiratory
sequelae.
Our findings are consistent with large population based studies
of children born in the early 1900 s [18,19,20,31,32,33]. These
studies reported a 6–7% increased risk of restrictive lung disease in
mid adulthood from childhood pneumonia. These studies were of
high quality with careful data collection, assessment of pulmonary
function and ascertainment of sequelae. It has also been suggested
that malnourished children and poor children who live in over
crowded households and may have an even greater increased risk
of long term sequelae [3,23,34,35]. However, we were unable to
assess risk in low income settings as we included only one study
from a low income country. There were also only two studies from
Africa and none from Asia.
Our high risks in hospital patients are also consistent with other
studies [36,37,38]. Hospitalised children are more likely to have
severe sequelae than children who are treated at home [39].
Children who are hospitalised for pneumonia have severe disease
and require oxygen, intravenous antibiotics and some need
ventilatory support [36] [37]. They have longer duration of
illness, greater damage to lung parenchyma and bronchioles and
are more likely to develop nosocomial pneumonia infections with
virulent and antibiotic resistant organisms such as Pseudomonas and
Klebsiella spp [40,41].
We reported that young children under two years of age had a
higher risk of sequelae compared to older children but this
difference was not statistically significant. Other studies have
indicated that infants under 12 months have the highest risk of
pneumonia sequelae [3,19,20]. Indeed, it has been suggested that
lower respiratory tract infection at an early stage of lung
development may impair lung growth and reduce subsequent
lung function [3]. This could be due to harmful effects of the
disease on growing lungs or halted lung growth because of injury
[42].
Table 3. Characteristics of included studies, 1970–2011.
Non hospital non pathogen Hospital non pathogen Hospital pathogen Total
3 papers 3 papers 7 papers 13 papers
WHO region
Americas 0 0 2 (33%) 2 (15%)
Europe 3 (100%) 1 (33%) 2 (33%) 6 (46%)
Africa 0 2 (66%) 0 2 (15%)
Western Pacific 0 0 3 (43%) 3 (23%)
South East Asia 0 0 0 0
Eastern Mediterranean 0 0 0 0
GNI band (in $US per capita)
High ($12,196) 3 (100%) 1 (33%) 6 (86%) 10 (77%)
UMI (3,946–12,195) 0 1 (33%) 1 (14%) 2 (15%)
LMI (996–3945) 0 0 0
Low (#995) 0 1 (33%) 0 1 (8%)
Study design
Prospective 3 (100%) 3 (100%) 0 6 (46%)
Retrospective 0 0 7 (100%) 7 (54%)
Median age at infection
,2 years 3 (100%) 2 (66%) 1 (14%) 6 (46%)
$2 years 0 1 (33%) 6 (86%) 7 (54%)
Duration of follow up
,2 years 0 0 1 (14%) 1 (8%)
$2 years 3 (100%) 3 (100%) 6 (86%) 12 (92%)
Loss to followup
,25% 1 (33%) 1 (33%) 3 (43%) 5 (38%)
$25% 2 (66%) 2 (66%) 4 (57%) 8 (62%)
Proportion male
,50% 1 (33%) 1 (33%) 1 (14%) 3 (23%)
$50% 2 (66%) 2 (66%) 6 (86%) 10 (77%)
doi:10.1371/journal.pone.0031239.t003
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Figure 2. Meta-analysis of the risk of developing at least one major pneumonia sequela in children under five years by
hospitalisation status and pathogenic cause, 1970–2011.
doi:10.1371/journal.pone.0031239.g002
Table 4. Major pneumonia sequelae risk, by site and pathogen, 1970–2011.
Non hospital non
pathogen specific
Hospital non
pathogen specific
Hospital
pathogen specific Total
Risk (95%CI) Risk (95%CI) Risk (95%CI) Risk (95%CI)
3 papers 3 papers 7 papers 13 papers
At least one major sequela 5.5% (2.8–8.3%) 17.6% (10.9–24.3%) 11.1% (2.5–19.7%) 10.4% (5.4–15.4%)
Restrictive lung disease 5.5% (3.0–8.0%) 17.1% (10.7–23.5%) 5.7% (2.2–8.6%) 5.4% (2.5–10.2%)
Obstructive lung disease 0 0 2.8% (0.05–6.4%) 2.8% (0.8–6.4%)
Bronchiectasis 0 0 0.9% (0.69–8.7%) 0.9% (0.7–8.7%)
Multiple impairments - Bronchiectasis combinedwith restrictive
lung disease
0 0.5% (0.15–4.7%) 1.7% (0.87–4.9%) 1.2% (0.05–7.7%)
At least one minor sequela 1.6% (1.0–8.5%) 5.0% (3.3–8.5%) 7.5% (5.1–13.9%) 6.7% (2.2–11.2%)
Chronic bronchitis 1.6% (1.0–8.5%) 4.2% (2.6–8.1%) 2.8% (1.0–8.1%) 2.8% (1.8–8.1%)
Asthma 0 1.2% (1.3–9.5%) 0.9% (0.2–2.4%) 0.7% (0.2–4.2%)
Other abnormal pulmonary function 0 0 0 0
Other chronic respiratory disease 0 0 0 0
Multiple impairments - Chronic bronchitis combined with asthma 0 0 3.8% (1.6–5.1%) 3.2% (0.1–5.1%)
At least one major or minor sequela 7.1% (2.9–26.8%) 23.2% (13.3–32.8%) 18.6% (15.0–23.4%) 17.1 (7.6–6.6%)
95%CI = 95% confidence interval.
doi:10.1371/journal.pone.0031239.t004
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Table 5. Regression analyses of the effect of explanatory variables on major pneumonia sequelae risk in children under five years,
1970–2011.
Studies
(n =13) Participants
Subgroup
estimates
Univariable
regression
Multivariable
regression
Children
examined (n)
Major sequelae
cases (n) Risk (95% CI)
Odds ratio
(95% CI)
Adjusted odds
ratio* (95% CI)
Cause
Non pathogen specific 6 (%) 489 49 10.9% (5.4–0.16.4%) 1 1
Pathogen specific 7 (%) 233 28 11.1% (2.5–19.7%) 1.60 (0.27–9.59) 3.33 (0.62–18.1)
P value = 0.605 P value = 0.608
Hospitalisation status
Non hospitalised 3 (%) 325 19 5.5% (2.8–8.3%) 1 1
Hospitalised 10 (%) 397 58 13.6% (6.2–21.1%) 1.93 (0.26–14.2) 3.65 (1.96–6.80)
P value = 0.517 P value = 0.003
Median age at infection
2 years 7 (%) 439 40 13.4% (4.5–22.3%) 1 -
$2 years 6 (%) 283 37 8.7% (3.1–14.3%) 0.82 (0.14–4.67) -
P value = 0.824 -
Proportion male
,50% 3 (%) 279 22 6.8% (1.0–12.6%) 1 -
$50% 10 (%) 443 55 13.0% (6.2–19.7%) 1.97 (0.25–15.4) -
P value = 0.516 -
Duration of follow up
,2 years 1 (%) 38 1 2.6% (24.2–9.5%) 1 -
$2 years 12 (%) 684 76 11.5% (6.0–16.9%) 5.51 (0.16–192.83) -
P value = 0.347 -
Loss to follow up
,25% 5 (%) 234 38 6.1% (1.8–10.4%) 1 1
$25% 8 (%) 488 39 24.8% (0.92–40.4%) 0.22 (0.048–1.05) 0.93 (0.47–1.81)
P value = 0.058 P value = 0.821
Study design
Prospective 7 (%) 489 49 10.9% (5.4–16.4%) 1 -
Retrospective 6 (%) 233 28 11.1% (2.5–19.7%) 0.62 (0.10–3.73) -
P value 0.605 -
WHO region
Americas 2 (%) 54 1 1.7% (24.0–7.4%) 1 -
Europe 6 (%) 431 41 11.6% (3.9–19.2%) 10.4 (0.45–240.0) -
Africa 2 (%) 130 21 15.7% (9.0–22.4%) 17.4 (0.54–561.4) -
Western Pacific 3 (%) 107 14 14.8% (21.4–30.9%) 11.9 (0.42–337.5) -
South East Asia 0 - - - - -
Eastern Mediterranean 0 - - - - -
P value = 0.286 -
GNI band (in $US per capita)
High ($12,196) 10 (%) 556 55 10.2% (4.4–16.1%) 1 -
UMI (3,946–12,195) 2 (%) 98 13 10.6% (25.6–26.8%) 0.91 (0.08–10.2) -
LMI (996–3945) 0 - - - - -
Low (#995) 4 (%) 68 9 13.2% (4.5–21.9%) 1.56 (0.07–34.1) -
P value = 0.811 -
*Adjusted for pathogenic cause of pneumonia, hospitalisation status, loss to followup.
doi:10.1371/journal.pone.0031239.t005
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Restrictive lung disease was the most common type of sequela.
This is in keeping with other studies which indicate that
pneumonia pathogens can damage interstitial lung parenchyma
causing acute lung consolidation [3,31]. Expansion and growth of
alveoli can be reduced resulting in reduced vital capacity and
proportional reduction in forced expiratory volume [19,43,44].
Pneumonia pathogens also can damage bronchiolar epithelium
and connective tissue resulting in bronchiolar dilatation, impaired
clearance of secretions and chronic suppurative lung disease
including bronchiectasis [43,44]. The link between childhood
pneumonia and obstructive lung disease is less clear. We reported
a low risk of obstructive lung disease and only after Adenovirus
infection. Other studies have also reported low risk of obstructive
lung disease after childhood pneumonia [6,19,20,31]. Interesting-
ly, increased risk of obstructive lung disease has been reported in
infants with intrauterine malnutrition born low birth weight
compared to normal birth weight infants [19,20]. This has been
attributed to impairment of airway growth and abnormally narrow
airway size at birth. However, we did report an increased risk of
asthma in hospitalised children with and without pathogen specific
pneumonia which requires more investigation.
Children who have poor respiratory function at birth are at risk
of developing both pneumonia and later long term respiratory
problems [3,45]. A signficant limitation of our meta-analysis and
other studies to date is the lack of information on baseline
respiratory status prior to the pneumonia episode. These baseline
data were not recorded in any of our included studies. However,
other studies have used birth weight as a proxy for early
respiratory function and investigated effects of birth weight on
pneumonia and long term respiratory outcomes [19,20]. These
studies demonstrated important associations between childhood
pneumonia and long term outcome even after adjusting for birth
weight. Other important confounders include cigarette smoking
and indoor airpollution [32,46], but we were also unable to control
for these factors in our multivariable analyses. We had no
information on human immunodeficiency virus (HIV) infection in
our study populations, and only two studies were conducted in
countries where HIV infection is highly prevalent [21,23].
There were other limitations to our meta-analysis. Firstly, our
median loss to follow up was 34% and it is likely that the loss to
follow up was differential; i.e. families with unwell children were
more likely to present for follow up than those with well children.
However, our studies had long follow up time (median 11 years) so
we were able to assess outcomes also in adulthood which is an
important time for ascertainment of respiratory sequelae [18,45].
Secondly, other disease syndromes such as septicaemia, dehydra-
tion, acidosis and malaria can be misclassified as pneumonia [1,3].
Radiologically confirmed consolidation is the gold standard for
diagnosis of pneumonia but radiological confirmation was only
available in the hospital studies. However, we used strict
pneumonia case definitions which required a pneumonia diagnosis
by a health professional. We also used GBD and ICD10
definitions to categorise our outcomes clearly and were able to
stratify sequelae into major, minor, specific domains and multiple
impairments. Finally, our included studies were heterogeneous
and could only be analysed in specific subgroups. Also, many had
small sample sizes. More long term follow up studies are needed,
especially population based birth cohort studies from low income
countries and studies with respiratory function ascertained soon
after birth.
Our study has a number of implications for program and policy
development. All children with pneumonia diagnosed by a health
professional should be considered to be at risk of long term
sequelae; even if the pneumonia episode is only a marker of pre-
existing respiratory dysfunction. Currently, most paediatricians
regard childhood pneumonia to be an acute disease with no need
for long term follow up if a child has no risk factors and a clear
chest radiograph. We consider that all children under five years
who have a diagnosis of pneumonia should have at least one follow
up appointment with a health professional after the acute
symptoms have resolved. Evaluation of childhood pneumonia
interventions should also include potential impact on long term
respiratory sequelae.
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